DE69227456D1 - Nachweis von kollagenabbau -i(in vivo) - Google Patents

Nachweis von kollagenabbau -i(in vivo)

Info

Publication number
DE69227456D1
DE69227456D1 DE69227456T DE69227456T DE69227456D1 DE 69227456 D1 DE69227456 D1 DE 69227456D1 DE 69227456 T DE69227456 T DE 69227456T DE 69227456 T DE69227456 T DE 69227456T DE 69227456 D1 DE69227456 D1 DE 69227456D1
Authority
DE
Germany
Prior art keywords
vivo
proof
collagen degradation
binding partner
immunological binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69227456T
Other languages
English (en)
Other versions
DE69227456T2 (de
Inventor
David R Eyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington Research Foundation
Original Assignee
Washington Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington Research Foundation filed Critical Washington Research Foundation
Publication of DE69227456D1 publication Critical patent/DE69227456D1/de
Application granted granted Critical
Publication of DE69227456T2 publication Critical patent/DE69227456T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69227456T 1991-05-31 1992-05-15 Nachweis von kollagenabbau -i(in vivo) Expired - Lifetime DE69227456T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/708,529 US5320970A (en) 1987-11-06 1991-05-31 Detection of collagen degradation in vivo
PCT/US1992/004104 WO1992021698A1 (en) 1991-05-31 1992-05-15 DETECTION OF COLLAGEN DEGRADATION $i(IN VIVO)

Publications (2)

Publication Number Publication Date
DE69227456D1 true DE69227456D1 (de) 1998-12-03
DE69227456T2 DE69227456T2 (de) 1999-06-24

Family

ID=24846153

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69227456T Expired - Lifetime DE69227456T2 (de) 1991-05-31 1992-05-15 Nachweis von kollagenabbau -i(in vivo)

Country Status (10)

Country Link
US (4) US5320970A (de)
EP (3) EP0884055A1 (de)
JP (1) JPH06508138A (de)
KR (1) KR100249101B1 (de)
AT (1) ATE172743T1 (de)
AU (1) AU665953B2 (de)
CA (1) CA2110263A1 (de)
DE (1) DE69227456T2 (de)
IE (1) IE921772A1 (de)
WO (1) WO1992021698A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962639A (en) * 1987-11-06 1999-10-05 Washington Research Foundation Synthetic peptides corresponding to telopeptide sequences of cross-linked type I collagen metabolites
US6027903A (en) * 1987-11-06 2000-02-22 Washington Research Foundation Kit for detecting analyte indicative of type I collagen resorption in vivo
US6153732A (en) * 1987-11-06 2000-11-28 Washington Research Foundation Kit for detecting analyte indicative of type II collagen resorption in vivo
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
CA2152667C (en) * 1992-12-28 2003-02-11 David J. Baylink Bone resorption assay
US6110689A (en) * 1994-01-21 2000-08-29 Osteometer A/S Method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen
GB9506050D0 (en) 1995-03-24 1995-05-10 Osteometer A S Assaying collagen fragments in body fluids
EP0787301B1 (de) 1994-10-17 2001-02-14 Osteometer Biotech AS Einschätzung der fragmentierungsmuster von kollagen in körperflüssigkeiten und diagnose von mit dem kollagenmetabolismus zusammenhängenden störungen
EP0718309B1 (de) * 1994-12-23 1999-04-07 Roche Diagnostics GmbH Antigene und Antikörper zum Nachweis von Kollagen I
US5750647A (en) * 1995-05-19 1998-05-12 Washington Research Foundation Synthetic peptide analogs of NTx
US5608249A (en) 1995-11-16 1997-03-04 Micron Technology, Inc. Reduced area storage node junction
US6107047A (en) * 1996-03-21 2000-08-22 Osteometer Biotech A/S Assaying protein fragments in body fluids
GB9617616D0 (en) 1996-08-22 1996-10-02 Osteometer Biotech As Assaying protein fragments in body fluids
WO1998026286A2 (en) * 1996-12-09 1998-06-18 Osteometer Biotech A/S Sandwich assays for collagen type i fragments
US5989925A (en) * 1997-06-27 1999-11-23 Serex, Inc. Antibody to and assay for peptide linked-pyridinoline as indicator of bone resorption level
EP1010007B1 (de) * 1997-07-31 2004-01-21 Metra Biosystems, Inc. Testverfahren für collagenpeptid
US6117646A (en) * 1997-09-22 2000-09-12 Osteometer Biotech A/S Assaying protein fragments in body fluids
US6030792A (en) * 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
US6602980B1 (en) 1998-06-19 2003-08-05 Washington Research Foundation Collagen type III synthetic peptides for collagen resorption assays
DE19980834T1 (de) 1998-06-19 2001-06-13 Washington Res Found Knorpel-Resorptionstests
US6348320B1 (en) 1998-06-19 2002-02-19 Washington Research Foundation Cartilage resorption assays measuring type II collagen fragments
US6916903B2 (en) * 1998-06-19 2005-07-12 Washington Research Foundation Collagen type III synthetic peptides for collagen resorption assays
US6642007B1 (en) 1998-11-02 2003-11-04 Pfizer Inc. Assays for measurement of type II collagen fragments in urine
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
PT1149111E (pt) * 1999-01-06 2009-11-19 Univ Southern California Processo e composição para a inibição da angiogénese
WO2000040974A1 (en) * 1999-01-07 2000-07-13 Quidel Corporation Pyridinium crosslinks assay
DE60042487D1 (de) * 1999-07-13 2009-08-13 Univ Southern California Methode und zusammensetzung zur angiogenese-inhibierung mit antagonisten gegen mmp-9 und beta1-integrine
JP2004510981A (ja) 2000-10-03 2004-04-08 ロウェット、リサーチ、インスティテュート ピロール含有生体化合物の測定方法およびピロール含有生体化合物
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
US20070231788A1 (en) * 2003-12-31 2007-10-04 Keyvan Behnam Method for In Vitro Assay of Demineralized Bone Matrix
EP1701729B1 (de) 2003-12-31 2018-05-02 Warsaw Orthopedic, Inc. Verbesserte knochenmatrixzusammensetzungen und verfahren
US8734525B2 (en) 2003-12-31 2014-05-27 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
WO2006020231A2 (en) * 2004-07-21 2006-02-23 Medtronic, Inc. Medical devices and methods for reducing localized fibrosis
CA2573671A1 (en) * 2004-07-21 2006-02-23 Medtronic, Inc. Methods for reducing or preventing localized fibrosis using sirna
US7763418B2 (en) * 2005-07-05 2010-07-27 Cytoskeleton, Inc. Detection of Rho proteins
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
CN101365499A (zh) 2005-11-01 2009-02-11 骨骼技术股份有限公司 骨基质组合物和方法
US20080124813A1 (en) * 2006-11-17 2008-05-29 Phoenix Pharmaceuticals, Inc. Bead-based radioimmunoassay
US9554920B2 (en) 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
CA2690457C (en) 2007-06-15 2018-02-20 Osteotech, Inc. Bone matrix compositions and methods
CA2945295C (en) * 2007-06-15 2020-01-14 Warsaw Orthopedic, Inc. Method of treating tissue
WO2009009684A1 (en) * 2007-07-10 2009-01-15 Osteotech, Inc. Delivery system
US20110054408A1 (en) * 2007-07-10 2011-03-03 Guobao Wei Delivery systems, devices, tools, and methods of use
EP2211921B1 (de) 2007-10-19 2013-12-25 Warsaw Orthopedic, Inc. Demineralisierte knochenmatrix-zusammensetzungen und verfahren
WO2009153783A1 (en) * 2008-06-16 2009-12-23 Mor Research Applications Ltd. Monitoring skin metabolism products for evaluating burn injury
WO2010093955A1 (en) 2009-02-12 2010-08-19 Osteotech,Inc. Segmented delivery system
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
EP2536285B1 (de) 2010-02-18 2018-04-25 vTv Therapeutics LLC Substituierte kondensierte imidazolderivate, pharmazeutische verbindungen und verwendungsverfahren dafür
CN107981233A (zh) * 2017-11-29 2018-05-04 银川伊百盛清真食品有限公司 牛、羊骨生物酶解及肽、钙分离提取方法
JPWO2023068248A1 (de) * 2021-10-20 2023-04-27

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (de) * 1967-12-11 1969-06-13
US4094646A (en) * 1977-06-02 1978-06-13 The Baltimore Spice Company Rapid method of assaying collagen in meat and meat products
DE2816841A1 (de) * 1978-04-18 1979-10-31 Max Planck Gesellschaft Radioimmunologische bestimmung von prokollagen (typ iii) und prokollagen- peptid (typ iii)
US4298593A (en) * 1979-08-21 1981-11-03 Abbott Laboratories Reagents and methods utilizing labeled Fab bound to antigens
US4371374A (en) * 1980-11-17 1983-02-01 The Rockefeller University Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine
DE3209149A1 (de) * 1982-03-13 1983-10-06 Hoechst Ag Verfahren zur gemeinsamen immunologischen bestimmung von prokollagen-peptid (typ iii) und prokollagen-peptid col 1 (typ iii) und verfahren zur herstellung von anti-prokollagen-peptid col 1 (typ iii)-serum
US4628027A (en) * 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
EP0128041A3 (de) * 1983-06-06 1986-12-03 David Jeston Baylink Polypeptide mit einer Skelettwachstumsfaktor-Wirksamkeit
US4731326A (en) * 1984-06-04 1988-03-15 Ortho Diagnostic Systems Inc. Disease diagnosis by detection of shed normal tissue antigens
US4774227A (en) * 1986-02-14 1988-09-27 Collagen Corporation Collagen compositions for bone repair containing autogeneic marrow
EP0289314B1 (de) * 1987-04-28 1994-10-12 Roche Diagnostics GmbH Verwendung von IGF-II zur Behandlung von Knochenkrankheiten
GB2205643B (en) * 1987-05-08 1991-03-13 Farmos Group Limited Type iii collagen degradation assay
US5300434A (en) * 1987-11-06 1994-04-05 Washington Research Foundation Hybridoma cell line producing an antibody to type-I collagen amino-terminal telopeptide
US4973666A (en) * 1987-11-06 1990-11-27 Washington Research Foundation Peptide fragments containing HP and LP cross-links
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
GB8815174D0 (en) * 1988-06-25 1988-08-03 Rowett Research Inst Method of monitoring collagen degradation
EP0439545A4 (en) * 1988-10-24 1991-10-23 Bruce Caterson Methods of and compositions for diagnosing, monitoring and treating the early stages of osteosarthritis
WO1990008195A1 (en) * 1989-01-13 1990-07-26 President And Fellows Of Harvard College Monoclonal antibody to human type ix collagen
DE3934569A1 (de) * 1989-10-17 1991-04-25 Rudolf August Kuerten Verfahren zum zustellen einer druckrakel und einer flutrakel beim siebdruck
GB9105893D0 (en) * 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation

Also Published As

Publication number Publication date
ATE172743T1 (de) 1998-11-15
JPH06508138A (ja) 1994-09-14
WO1992021698A1 (en) 1992-12-10
US5320970A (en) 1994-06-14
EP0587719B1 (de) 1998-10-28
EP0587719A1 (de) 1994-03-23
EP0587719A4 (de) 1994-11-02
EP0884328A1 (de) 1998-12-16
AU665953B2 (en) 1996-01-25
DE69227456T2 (de) 1999-06-24
CA2110263A1 (en) 1992-12-10
EP0884055A1 (de) 1998-12-16
US5472884A (en) 1995-12-05
AU2140992A (en) 1993-01-08
IE921772A1 (en) 1992-12-02
US5688652A (en) 1997-11-18
KR100249101B1 (ko) 2000-03-15
US5912131A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
DE69227456D1 (de) Nachweis von kollagenabbau -i(in vivo)
DE69840334D1 (de) Puffern zur stabilizierung von hcv antigenen
DK0724456T3 (da) CD40-Antistoffer
IS2508B (is) Mótefni gegn ED-B hneppinu í fíbrónektíni, smíði þeirra og notkanir
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
EP1140175A4 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
NZ568769A (en) Human monoclonal antibodies against CD20
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
ES8800274A1 (es) Un procedimiento para la preparacion de un polipeptido-c-terminal p21ras
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
NO982715D0 (no) Endotel celle-proliferasjonsinhibitor og fremgangsmÕte for anvendelse
DE59508474D1 (de) RHEUMAFAKTOR-ENTSTÖRUNG MIT ANTI-Fd-ANTIKÖRPERN
ATE132162T1 (de) Humane gammainterferonantagonisten
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
ES2042461T3 (es) Producto y procedimiento para el teñido oxidativo del cabello.
HK1021228A1 (en) In vitro method for determining the presence of hepatocellular carcinoma
TR199801027T2 (xx) Epitelyom te�his ve tedavisi i�in y�ntem.
ATE170631T1 (de) Verfahren und zusammensetzung zur verminderung der effekte von endogener alkalischer phosphatase
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
ES2115750T3 (es) Ensayo de captura de proteinas de union.
SE0002835D0 (sv) Method and kit for production of monoclonal antibodies
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum

Legal Events

Date Code Title Description
8364 No opposition during term of opposition